Preparing for change before change beckons. Harnessing the power of innovative research. Providing high-quality medicines for a healthier world. This is our world at Wockhardt.
Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.
The Company has a market capitalisation of
over US$ 1 billion and an annual turnover of US$ 650 million. Wockhardt’s pace of growth and momentum permeates every mindset, system and technology within the organisation.
Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with more than 65% of its revenue coming from Europe and the United States. Wockhardt’s market presence covers formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).
| The Company has its headquarters in India, and has |
|
14 manufacturing plants in India, UK, Ireland, France and US |
|
Subsidiaries in US, UK,
Ireland and France |
|
Marketing offices in Africa, Russia, Central and South East Asia. |
|
Wockhardt has a strong track record in acquisition management, with five successful acquisitions in the European market. These acquisitions have strengthened Wockhardt’s position in the high-potential markets of Europe, and have expanded the global reach of the organisation.
| Wockhardt’s manufacturing facilities in India, UK, Ireland, France and US
have the approval of major regulatory bodies, including US FDA and UK's MHRA, with capabilities for both Finished Dosage Formulations and APIs. The output includes |
|
Steriles (Injectables) |
|
Biopharmaceuticals |
|
Orals (Tablets & Liquids) |
|
Topicals (Creams & Ointments). |
| Wockhardt is a partner of choice for manufacturing, having entered into manufacturing alliances with leading pharmaceutical and biotechnology majors, including |
|
Astra Zeneca |
|
Lab Aguettant |
|
Aventis |
|
Amylin |
|
Schering-Plough |
|
Eisai |
|
Cell Therapeutics |
|
LSI, UK |
|
AFT, New Zealand |
|
Ebewe, Austria |
A key growth driver at Wockhardt is its state-of-the-art, multi-disciplinary research capability backed by a team of 500 skilled scientists. Consistent efforts have resulted in six breakthrough biotechnology products, 750+
patent filings and a pipeline of promising new molecules.
Wockhardt’s strategies are aligned towards being a significant player in the emerging global biopharmaceuticals market. In order to achieve this goal, the company has set up the Wockhardt Biotech Park, India’s largest biopharmaceuticals complex, with six dedicated plants built to international standards.
